Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine: a serotonin-specific, second-generation antidepressant.

R W Sommi, M L Crismon, C L Bowden

    Pharmacotherapy
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The implications of hypersomnia in the context of major depression: Results from a large, international, observational study.

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2019
    Same author

    Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features.

    Acta psychiatrica Scandinavica·2017
    Same author

    Integrated transcriptome and methylome analysis in youth at high risk for bipolar disorder: a preliminary analysis.

    Translational psychiatry·2017
    Same author

    Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.

    Acta psychiatrica Scandinavica·2015
    Same author

    Relationships between mixed features and borderline personality disorder in 2811 patients with major depressive episode.

    Acta psychiatrica Scandinavica·2015
    Same author

    Common sources of disparate results and experience in clinical practice vs. results from phase 2 registration studies: lamotrigine as a prototype.

    Acta psychiatrica Scandinavica·2015

    Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), effectively treats major depression with a low side effect profile. Its efficacy is comparable to tricyclic antidepressants, making it a valuable option for patients unresponsive to other treatments.

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Psychiatry

    Background:

    • Fluoxetine is a novel bicyclic antidepressant.
    • It selectively inhibits presynaptic serotonin reuptake.
    • It has minimal impact on other neurotransmitters or receptor sites.

    Purpose of the Study:

    • To describe the pharmacokinetics and clinical profile of fluoxetine.
    • To evaluate its efficacy and safety in treating major depression.
    • To compare its therapeutic potential with existing antidepressant agents.

    Main Methods:

    • Pharmacokinetic analysis of oral administration, bioavailability, Tmax, protein binding, and elimination half-life.
    • Assessment of efficacy in major depression, obsessive-compulsive disorder, and intention myoclonus.

    Related Experiment Videos

  • Evaluation of side effect frequency and overdose reports.

    • Main Results:

    • Fluoxetine is well absorbed, with a long elimination half-life (1-3 days single dose, averaging 4 days long-term).
    • Its active metabolite, norfluoxetine, also inhibits serotonin reuptake with a 7-day half-life.
    • Efficacy is comparable to tricyclics; optimal dosage is 20-40 mg daily. Side effects are infrequent and dose-related.
    • Overdose reports show mild effects with no fatalities.

    Conclusions:

    • Fluoxetine is an effective antidepressant with a favorable safety profile.
    • It offers a valuable alternative for patients who do not respond to or tolerate tricyclic agents.
    • Its use in obsessive-compulsive disorder and intention myoclonus requires further investigation.